Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06625593 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumor, sponsored by BeOne Medicines.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 168
- Enrollment target
- 20
- Study locations
NCT06625593: Recruiting Phase 1 study of Advanced Solid Tumor, sponsored by BeOne Medicines.
NCT06625593 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by BeOne Medicines. The registered enrollment target is 168 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (12% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06625593, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by BeOne Medicines.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 168 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C137 alone and in combination with anticancer agents in participants with advanced solid tumors. The study will be conducted in two phases: Phase 1a (Monotherapy Dose Escalation, and Safety Expansion; Combination Dose Confirmation and Safety Expansion) and Phase 1b (Dose Expansion).
Primary Outcome
Number of participants with AEs and SAEs as graded by the National Cancer Institute- Common Terminology Criteria for Adverse Events Version (NCI CTCAE 5.0)), including AEs that meet protocol-defined dose-limiting toxicity (DLT) criteria and AEs meeting protocol-defined adverse event of clinical interest (AECIs)
Conditions Studied
Interventions
- DRUG BG-C137
- DRUG Anticancer Agents
Study Locations (20)
New South Wales
- Blacktown Cancer and Haematology Centre - Blacktown
- Liverpool Hospital - Liverpool
Victoria
- Monash Health - Clayton
- Cabrini Hospital Malvern - Malvern East
Henan
- The First Affiliated Hospital of Henan University of Science and Technology - Luoyang
- Henan Cancer Hospital - Zhengzhou
California
- Usc Norris Comprehensive Cancer Center (Nccc) - Los Angeles
Connecticut
- Yale Cancer Center - New Haven
Minnesota
- Mayo Clinic Rochester - Rochester
Texas
- Md Anderson Cancer Center - Houston
Washington
- Fred Hutchinson Cancer Research Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2024-12-09 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
What NCT06625593 shows while recruiting
NCT06625593 is an interventional study that assigns participants to a tested intervention. The registered 168 participants enrollment target is mid-sized for trials with a published cap, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (12% lower).
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which BG-C137 is the first listed.
NCT06625593 names 20 study sites across 17 states, led by New South Wales, Victoria, Henan.
Frequently Asked Questions
What is clinical trial NCT06625593 about?
NCT06625593 is a clinical study titled "A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C137 alone and in combination with anticancer agents in participants with advanced solid tumors. The study will be conducted in two phases: Phase 1a (M...
What is the current status of trial NCT06625593?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 168 participants. The study started on 2024-12-09. Estimated completion is 2026-12-31.
What conditions does trial NCT06625593 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT06625593?
The interventions under investigation include: BG-C137 (DRUG), Anticancer Agents (DRUG).
Who is sponsoring clinical trial NCT06625593?
This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06625593 being conducted?
This trial has 20 study locations across California, Connecticut, Minnesota, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06625593's enrollment target sits among peer trials
168 75th of 189 higher than 114 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02118922 · 168 participants
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
- NCT03536897 · 168 participants
IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry
- NCT04078230 · 168 participants · NA
Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma
- NCT04159168 · 168 participants · NA
Facial Affect Sensitivity Training for Young Children With Callous-unemotional Traits
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI